NewsFeed Voices Science Insight Innovation
November, 2025
November 2025
M T W T F S S
 12
3456789
10111213141516
17181920212223
24252627282930
Wolfgang Miesbach Discusses AAV Gene Therapy Safety in Hemophilia B: NEJM Correspondence Highlights Cancer Monitoring
Wolfgang Miesbach/Linkedin
Aug 22, 2025, 14:52

Wolfgang Miesbach Discusses AAV Gene Therapy Safety in Hemophilia B: NEJM Correspondence Highlights Cancer Monitoring

Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared a post on Linkedin:

“Happy to Share: Our NEJM Correspondence on AAV Gene Therapy in Severe Hemophilia B is Published Today! I am delighted that our letter to the editor on gene therapy and cancer surveillance—written together Flora Peyvandi and Glenn Pierce —is now published in the New England Journal of Medicine (NEJM)!

This correspondence addresses the recent 13-year follow-up paper by Ulrike Reiss et al., reporting two cancer cases after AAV gene therapy. Importantly, out of the total number of malignancies reported so far in hemophilia gene therapy trials, a relation to gene therapy has always been excluded.

AAV gene therapy offers transformative clinical benefits, but even rare theoretical risks (such as vector integration) require our field to be proactive, and vigilant.

Our comment emphasizes why molecular safety monitoring should go far beyond basic PCR, advocating for robust standards like vector integration mapping and whole-genome sequencing and standardisation of methods is needed.

We also call for harmonized international frameworks (e.g., the WFH-GTR registry) and industry-supported, accessible postmarketing monitoring—ensuring safety without burdening patients.”

Find more information here.

Stay in tune with Hemostasis Today.

AAV Gene Therapy bleeding disorders Gene therapy Hematology Hemophilia B Hemostasis Hemostasis Today New England Journal of Medicine (NEJM) Severe Hemophilia B Wolfgang Miesbach
NewsFeed